Patents by Inventor Koichiro Fukuda
Koichiro Fukuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230042358Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: December 11, 2019Publication date: February 9, 2023Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Jun CHIBA, Yoshito TERAO, Masanori KAWASAKI
-
Patent number: 11319286Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: August 2, 2018Date of Patent: May 3, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
-
Patent number: 11292766Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: GrantFiled: December 13, 2019Date of Patent: April 5, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
-
Publication number: 20220081399Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: ApplicationFiled: January 21, 2021Publication date: March 17, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
-
Publication number: 20220017514Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: December 11, 2019Publication date: January 20, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Yoshito TERAO, Masanori KAWASAKI
-
Patent number: 11168597Abstract: In a hybrid vehicle, suppression of an amount of fuel consumed for reducing NOx stored in an NSR catalyst and suppression of deterioration in exhaust gas components due to unreacted fuel flowing out from the NSR catalyst are made compatible with each other. Predetermined power source control is carried out in accompany with the execution of NOx reduction processing to supply fuel to the NSR catalyst. In the predetermined power source control, an engine rotation speed of an internal combustion engine is made to decrease or an operation of the internal combustion engine is made to stop, and an electric motor is controlled so as to compensate for required torque. Further, during a period of execution of the predetermined power source control, a lower limit value of a predetermined target SOC range for an SOC of a battery is changed to a value smaller than at times other than the period of execution of the predetermined power source control.Type: GrantFiled: January 16, 2019Date of Patent: November 9, 2021Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventor: Koichiro Fukuda
-
Publication number: 20210340114Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: April 9, 2021Publication date: November 4, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 11143128Abstract: An exhaust purification system of an internal combustion engine includes a catalyst arranged in an exhaust passage of the internal combustion engine and able to store oxygen, a storage amount calculating part configured to calculate an oxygen storage amount of the catalyst, a poisoning amount calculating part configured to calculate a poisoning amount of the catalyst, and an oxygen amount control part configured to control an amount of oxygen supplied to the catalyst based on the oxygen storage amount and the poisoning amount.Type: GrantFiled: December 24, 2019Date of Patent: October 12, 2021Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Ryosuke Kayanuma, Kenji Furui, Koichiro Fukuda
-
Publication number: 20210269420Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: June 27, 2019Publication date: September 2, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
-
Patent number: 10975043Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: January 27, 2020Date of Patent: April 13, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20200385346Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: August 2, 2018Publication date: December 10, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
-
Publication number: 20200208586Abstract: An exhaust purification system of an internal combustion engine includes a catalyst arranged in an exhaust passage of the internal combustion engine and able to store oxygen, a storage amount calculating part configured to calculate an oxygen storage amount of the catalyst, a poisoning amount calculating part configured to calculate a poisoning amount of the catalyst, and an oxygen amount control part configured to control an amount of oxygen supplied to the catalyst based on the oxygen storage amount and the poisoning amount.Type: ApplicationFiled: December 24, 2019Publication date: July 2, 2020Inventors: Ryosuke KAYANUMA, Kenji FURUI, Koichiro FUKUDA
-
Publication number: 20200157062Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasak
-
Publication number: 20200115399Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: ApplicationFiled: December 13, 2019Publication date: April 16, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
-
Patent number: 10544111Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: December 21, 2018Date of Patent: January 28, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 10508083Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: GrantFiled: February 1, 2017Date of Patent: December 17, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto
-
Publication number: 20190263843Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: ApplicationFiled: May 13, 2019Publication date: August 29, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko Fujimoto, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
-
Publication number: 20190226373Abstract: In a hybrid vehicle, suppression of an amount of fuel consumed for reducing NOx stored in an NSR catalyst and suppression of deterioration in exhaust gas components due to unreacted fuel flowing out from the NSR catalyst are made compatible with each other. Predetermined power source control is carried out in accompany with the execution of NOx reduction processing to supply fuel to the NSR catalyst. In the predetermined power source control, an engine rotation speed of an internal combustion engine is made to decrease or an operation of the internal combustion engine is made to stop, and an electric motor is controlled so as to compensate for required torque. Further, during a period of execution of the predetermined power source control, a lower limit value of a predetermined target SOC range for an SOC of a battery is changed to a value smaller than at times other than the period of execution of the predetermined power source control.Type: ApplicationFiled: January 16, 2019Publication date: July 25, 2019Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventor: Koichiro FUKUDA
-
Publication number: 20190119225Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 10214498Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: October 22, 2015Date of Patent: February 26, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki